| Similar Articles |
|---|
 |
The Motley Fool
September 20, 2005
Rich Smith |
ViaCell's Cancer Trial Snag The cord blood collector suffers a research setback. Investors should keep in mind that the real money-maker behind ViaCell is its ViaCord cord blood storage business.   |
The Motley Fool
February 23, 2007
Rich Smith |
Foolish Forecast: ViaCell Doing Well? The cord blood specialist is set to report its fourth-quarter and full-year 2006 numbers shortly. Investors, here is what you can expect to see. |
The Motley Fool
May 4, 2006
Rich Smith |
ViaCell Looking Sickly As expected, the company remains solvent by virtue of one division: its ViaCord umbilical cord blood storage unit, which provided $11.9 million of the quarter's $12.1 million in revenues. But even that good news fails to outweigh the bad news. Investors, take note. |
The Motley Fool
April 27, 2007
Rich Smith |
Foolish Forecast: ViaCell Doing Swell? The cord blood specialist is set to release its first-quarter 2007 earnings. Investors, here is what you can expect to see. |
The Motley Fool
March 2, 2005
Rich Smith |
ViaCell Under the Microscope Cord blood collector makes its first earnings announcement tomorrow. Investors will likely be shining harsh lights on the company's financial statements. |
The Motley Fool
November 30, 2004
Rich Smith |
Breaking Rules and Saving Lives Cord blood offers an ethical means of using stem cells to heal illness. While two top companies in the field are private, over the counter traded Cryo-Cell lost as much money as it collected in revenues last year. |
The Motley Fool
August 13, 2007
Rich Smith |
ViaCell Sees the Light Despite rising sales at its trademark ViaCord umbilical cord blood storage service, and gross margin from this service rising in tandem, the firm's operating and net results remain mired in thick red ink. Investors, take note. |
The Motley Fool
August 2, 2006
Rich Smith |
Foolish Forecast: Anemic ViaCell The cord blood storage specialist is due to report its second quarter 2006 numbers tomorrow. Investors, take note. |
BusinessWeek
June 27, 2005
Arlene Weintraub |
Stem Cells To Go ViaCell's goal is to mass-produce stem cells from umbilical cord blood. |
The Motley Fool
January 4, 2005
Rich Smith |
Blood for Sale Cord blood harvester ViaCell moves closer to its IPO, with pricing to be in the $7 to $9 range and will float 7.5 million shares, though still on a date "to be announced." |
The Motley Fool
August 8, 2007
Rich Smith |
Foolish Forecast: Watch for ViaCell to Tip Its Hand Will second-quarter results from cord-blood storage specialist ViaCell meet or exceed the relatively low management expectations? And will the next quarter improve, as the company has previously predicted? |
The Motley Fool
May 1, 2007
Rich Smith |
The Losses Swell at ViaCell Given that ViaCell has been ramping up its sales and marketing spending for about a year, it's about time ViaCell's stock start showing some results from this "investment." |
The Motley Fool
August 8, 2006
Rich Smith |
Second Opinion on ViaCell The prognosis isn't good. Is there still hope for ViaCell? Of course! Hope springs eternal. If ViaCell can just tighten its purse strings, investors may yet find a way to save blood and make money. |
The Motley Fool
October 2, 2007
Brian Orelli |
PerkinElmer and ViaCell: A Bloody Good Deal? PerkinElmer buys umbilical cord storage company ViaCell for $300 million. Investors, take note; the merger may be a good fit for both companies. |
The Motley Fool
April 3, 2006
Seth Jayson |
No Stemming the Flow of Shares Another year, another large dollop of shares to water down the juice at StemCells. This company excels at burning money, as its cash flow statements show. Invest accordingly. |
The Motley Fool
August 27, 2007
Brian Orelli |
Repairing a Broken Heart Stem cells may be the new cure. If research continues on track, Geron expects to ask FDA to start clinical trials late next year or in early 2009. Investors, take note. |
The Motley Fool
April 18, 2005
Rich Smith |
U.S. Government Out for Blood Two companies await as the Institute of Medicine advocates improvements in cord blood banking. Newly public ViaCell has been plummeting along with rival Cryo-Cell, down roughly 40% over the past three months. |
The Motley Fool
August 31, 2007
Brian Orelli |
A Stem-Cell Primer Public funding from states could help companies doing stem cell research. Read about Geron, StemCells, Osiris Therapeutics, ViaCell and Invitrogen, companies that may profit from the increased public spending. |
The Motley Fool
August 19, 2010
Brian Orelli |
The Mice Can Walk! Remember you're essentially buying a lottery ticket investing in this or any other unproven early stage biomedical technology. |
The Motley Fool
May 2, 2011
Brian Orelli |
StemCells Up for All the Right Reasons Federal funding doesn't matter for most stem cell companies. |
The Motley Fool
January 25, 2005
Rich Smith |
ViaCell's Costly Mistake Cord blood harvester neglects to collect the cash with an undervalued IPO. |
The Motley Fool
November 9, 2004
Charly Travers |
Are Stem Cells a Rule Breaker? Does the science offer real hope or just hype? Biotech investors take on enough risk in the normal course of drug development that they do not need to worry about whether or not the underlying technology even works. |
The Motley Fool
July 26, 2004
Brian Gorman |
Stem Cell Researcher a Risk Geron could benefit from a new U.S. president, but in the end, studies of embryonic stem cells may or may not yield breakthroughs, so buying their stock now would be a gamble. |
The Motley Fool
July 14, 2011
Rich Smith |
What's All the Fuss About Stem Cells? Stocks are up on news of Sweden's miracle meatball. Over the weekend, Swedish researchers announced the successful transplant of an artificial trachea to a patient whose own organ had been ravaged by cancer. |
The Motley Fool
March 5, 2007
Rich Smith |
ViaCell Not Doing Well The company's biotech half continues to sap revenue from the moneymaking side. Investors, take note. |
The Motley Fool
October 12, 2010
Travis Hoium |
Geron Shares Popped: What You Need to Know Geron shares jumped 10% after the company announced that its first patient has enrolled in the company's stem cell clinical trial. |
The Motley Fool
February 2, 2005
Rich Duprey |
Aastrom to Leap Into Trials The biotech firm advances to the next stage of clinical studies in stem cell research. Investors, take note. |
Popular Mechanics
December 16, 2008
Michael Milstein |
Bringing Stem Cells to War: Meet the Blood Pharmers Fresher blood is better than stale: It carries more oxygen and, when transfused into patients, speeds recovery. |
BusinessWeek
May 24, 2004
Arlene Weintraub |
Want To Bank Your Own Stem Cells? One Los Angeles startup believes everyone should, to be ready when regenerative therapies start hitting the market |
Bio-IT World
Dec 2005/Jan 2006
Maureen McDonough |
The Century of the Cell Like most new life science industries, the stem cell business landscape looks like a maze. There are many paths, turns, and dead-ends, but it is quite possible that there will be more than one route to the finish line. |
Salon.com
July 17, 2000
Alix Christie |
The cord-blood controversy First we were supposed to eat the placenta. Now we're supposed to freeze it. |
The Motley Fool
September 6, 2007
Rick Aristotle Munarriz |
Britain Unleashes the Wolfman The chimerical future is here. Britain's Human Fertilization and Embryo Authority announced that it will permit scientists to create human-animal hybrid embryos. |
The Motley Fool
May 3, 2005
Charly Travers |
Is Geron a Rule Breaker? At the forefront of stem cell research, can the company live up to its lofty potential? Geron's science is hot. Its stock is not. |
HHMI Bulletin
May 2010
Sarah C.P. Williams |
Young Again Niche cells can reverse the aging of stem cells. |
The Motley Fool
May 26, 2009
Brian Orelli |
A Less-Risky Stem Cell Play Life Technologies is a clear leader in stem cell reagents. |
The Motley Fool
January 31, 2011
Brian Orelli |
Time to Buy Into Stem Cells? New developments bring this analyst a step closer to opening his wallet. |
The Motley Fool
October 14, 2005
Tim Beyers |
Baby Breaker Birth Announcements We track the week in private equity in search of investments of the future. Virxsys... Raven Biotechnologies... |
The Motley Fool
December 1, 2008
Brian Orelli |
Obama Can't Save Stem Cell Companies While government-sponsored research on embryonic stem cells might eventually help scientists better understand all stem cells, it's not likely to help the companies right now. |
The Motley Fool
September 29, 2010
Brian Orelli |
Careful What You Wish For, Stem Cell Investors Investors seem to have forgotten about fundamentals. |
Pharmaceutical Executive
October 1, 2012
Ben Comer |
Stem Cells: A Promise Deferred? Ideology, politics, and a stilted political debate may be causing pharma to overlook the potential of emerging stem cell therapies in fostering a new generation of cures. |
The Motley Fool
December 22, 2009
Brian Orelli |
Pfizer Swings for the Fences A long shot, but at least it's cheap. Pfizer seems to have taken a particular liking to stem cells, having established a unit to study them last year |
The Motley Fool
January 4, 2005
W.D. Crotty |
A StemCell First News of an FDA application sends StemCells' stock soaring. |
The Motley Fool
August 2, 2010
Brian Orelli |
Back in Love With Geron Investors' love / hate relationship with Geron is back in the worship phase, with the stem cells company up 17% on Friday and nearly an additional 10% or so today. |
The Motley Fool
November 15, 2011
Brian Orelli |
When Giving Up Is a Good Move in Biotech Geron calls it quits with stem cells. |
BusinessWeek
January 10, 2005
Bruce Einhorn |
Asia Is Stem Cell Central Singapore isn't the only country in the region trying to profit from the U.S. restrictions. Australia, China, India, Japan, and South Korea all see stem cell research as a way to get ahead in biotech. |
The Motley Fool
February 26, 2007
Rich Smith |
Foolish Forecast: Cryo-Cell Defrosting The cord-blood storage specialist will report its fourth-quarter and full-year financial news shortly. Investors, here is what you can expect to see. |
The Motley Fool
December 29, 2005
Rich Smith |
New Year's 2016: Four Fabulous Fads Today's passing fads are tomorrow's market dominators. Investing is already more art than science, and investing for 10 years in the future -- even more so. |
The Motley Fool
November 14, 2008
Brian Orelli |
Pfizer Takes the Plunge Into Stem-Cell Research The world's largest drugmaker by market cap announced today that it's forming a unit to focus on stem cells. |
